Obermatt
See Similar Stocks →

SCI Pharmtech

TAI:4119 · TW0004119003
PharmaceuticalsSmall

360

7
Medium confidence — indicative
Profit price94
Owner Earnings Yield1
Dividend Yield1
Price/Sales21
EV / Gross Profit19
Price/Book71
Return on Capital70
Cash Return on Capital54
Return on Equity66
EBIT Margin78
Gross Profitability23
Cash Conversion54
Accruals24
Owner Earnings Margin32
Sales growth62
Profit Growth30
Long-Term EPS Growth28
Reinvestment58
Price momentum13
Debt load57
Refinancing42
Debt Payback1
Liquidity75
Analyst ratings14
Expectations trend50
Market mood1
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

SCI Pharmtech doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryTaiwan
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeTWSE
Founded1987
Employees12
Websitesci-pharmtech.com.tw
ISINTW0004119003
Last UpdateApr 2, 2026
Index & Theme
Central Nervous SystemPain ManagementNeurologyBiotechnologyHealth CareManufacturingMedicalPharmaceutical

Description

Analysis

Middle-of-the-road

SCI Pharmtech, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 2/20 on our value-creation score: not creating value. Analyst sentiment is cautious.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
9
2023202420252026

All-time high

85

Jan 2023

All-time low

6

Mar 2026

Average rank

29

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
21
18
9
20
Price/Earnings
13
14
42
20
Price/Book
71
31
29
48
Dividend Yield
1
44
21
75
Value (overall)
17
22
16
35

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare SCI Pharmtech with its peers
Kyongbo Pharmaceutical
KSC:214390
11
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
J. B. Chemicals & Pharmaceuticals
NSI:JBCHEPHARM
69
CountrySingapore
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
CKD Bio
KSC:063160
—
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Daiichi Sankyo
TYO:4568
56
CountryJapan
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Korea United Pharm
KSC:033270
90
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
ST Pharm
KOE:237690
86
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →